Bone mass gain after parathyroidectomy  by Pasch, Andreas
Kidney International (2008) 74          697
commentar y
individual and collective roles in leading 
to increased mortality risk. It is critically 
important for patients and caregivers to 
understand whether too much of a good 
thing (ESA therapy) may be harmful to 
our patients.
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Bone mass gain after 
parathyroidectomy
Andreas Pasch1
Yajima and co-workers investigated iliac bone biopsies taken before and 
after parathyroidectomy. They found enhanced de novo osteoid formation 
and mineral apposition at trabecular sites without signs of previous 
bone resorption. From this finding they conclude that ‘minimodeling’ 
contributes to the increase of bone volume following parathyroidectomy. 
This report refines our understanding of the compensatory mechanisms 
by which bone mass and possibly increased mechanical stability of the 
skeletal apparatus are regained after parathyroidectomy.
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Secondary hyperparathyroidism and 
the resulting bone disorder osteitis fib-
rosa are serious and common problems 
in long-term dialysis, affecting about 
20%–30% of patients.1 High levels of 
parathyroid hormone (PTH) are asso-
ciated with a loss of bone mass and an 
elevated risk of bone fractures.2 Before 
the invention of calcimimetics, surgi-
cal removal of the enlarged parathyroid 
glands was the treatment of choice for 
secondary hyperpara thyroidism. Sur-
gery results in a net gain of bone mass 
of 7%–23% in 3 years2 and a reduction 
of fracture risk.3
High serum levels of PTH stimulate 
the release of RANKL from osteoblasts/
stromal cells and thereby indirectly stimu-
late osteoclast differentiation and devel-
opment and increase bone resorption. In 
parallel, osteoblasts are activated to com-
pensate for this loss of bone mass by the 
formation of new bone tissue at sites of 
prior bone resorption. Unfortunately, this 
mechanism, called remodeling, does not 
suffice to make up for the lost bone mass.3
In addition to remodeling, the existence 
of yet another regenerative mechanism, 
called minimodeling, has been suspected 
on the basis of an early publication from 
1964,4 but only recently did it regain 
attention. Histologically, minimodeling is 
characterized by the presence of smooth 
cement lines, whereas in remodeling, 
scalloped cement lines are encountered, 
which indicate the previous bone-resorp-
tive action of osteoclasts.5 Accordingly, 
minimodeling is defined by an exclusion 
criterion, the de novo generation of bone 
tissue at trabecular sites without signs of 
prior bone resorption, which makes it at 
times difficult to unequivocally identify 
these sites.5 Modeling (shaping and grow-
ing of bone, visible without a microscope) 
and minimodeling (shaping and de novo 
growth of bone, visible by microscope 
only) have been shown to be the pre-
dominating mechanisms of bone mass 
gain in periods of bone growth. This was 
demonstrated in a very elegant experiment 
in rats performed by Erben.6 In this study, 
minimodeling accounted for about 60% 
of bone formation in the proximal tibial 
metaphysis in 3-month-old rats, whereas 
remodeling accounted for about 20%. In 
12-month-old rats, this ratio had changed, 
with remodeling present in about 66% and 
minimodeling in about 16% of sites. In 
accordance with the hypothesis proposed 
by Frost that minimodeling can also occur 
in adult life,7 minimodeling was encoun-
tered in 21 of 34 human iliac crest biopsies 
of non-uremic patients undergoing hip 
replacement.8 Likewise, minimodeling 
was found in iliac crest biopsies of adult 
hemodialysis patients with secondary 
hyperparathyroidism.9 Therefore, it has 
been hypothesized that minimodeling 
is a mechanism of bone formation that 
can be reactivated as an additional adap-
tive mechanism to size and shape bone 
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in order to provide optimal mechani-
cal function.5 It is therefore a reasonable 
research approach to look for signs of the 
potentially bone-stabilizing mechanism of 
minimodeling in diseases characterized by 
a net loss of bone mass.
Yajima and colleagues10 (this issue) 
investigated iliac bone biopsies taken 
from 16 long-term hemodialysis patients 
with pronounced secondary hyperpar-
athyroidism. Biopsies were taken before 
and at 3–4 and 10–12 weeks after parathy-
roidectomy. Mean PTH levels were about 
1,230 pg/ml (normal = 10–65) before 
and about 30 pg/ml after surgery, during 
which a small piece of parathyroid tis-
sue was autotransplanted. As expected, 
serum levels of both bone resorption and 
formation markers dropped sharply after 
surgery. In parallel, the number of histo-
logically detectable osteoclasts dropped 
by about 95%. Also, the number of osteob-
lasts dropped, an effect more pronounced 
at remodeling than at minimodeling sites. 
At 3–4 weeks after surgery, osteoid volume 
at minimodeling sites (MI.OV/MI.BV 
= 42%) exceeded osteoid volume in the 
whole bone (OV/BV = 19%). Along with a 
more pronounced rise of osteoid formation 
and an enhanced mineral apposition rate, 
this indicates a more active bone formation 
at minimodeling sites. Importantly, mini-
modeling-derived bone volume (MI.BV/
BV) accounted for only 2% before parathy-
roidectomy, whereas by 10–12 weeks this 
fraction had increased to 9.5% of the total 
bone volume (Figure 1). From these find-
ings, the authors conclude that minimod-
eling accounted in part for the increase of 
bone volume after parathyroidectomy.
These data allow important new insights 
into bone formation in uremic patients 
before and after parathyroidectomy. They 
support the hypothesis that minimodeling 
is a mechanism by which the body tries to 
maintain stability and integrity by reacti-
vating a mechanism usually seen in child-
hood and phases of bone growth. However, 
the question of by which pathways bone 
formation at minimodeling sites is being 
activated has not been answered yet. One 
possibility is that high PTH levels inhibit 
minimodeling and, upon removal of PTH, 
minimodeling is reactivated to its normal 
and physiological level. Data from Koba-
yashi and co-workers8 argue against this 
possibility, because their minimodeling 
data in the presence of physiological PTH 
levels are comparable to the minimodeling 
data reported in the presence of elevated 
PTH levels before surgery by Yajima and 
co-workers.10 So, with the limitation that 
the data of Kobayashi et al.8 were collected 
in non-uremic patients, it seems that the 
gain in minimodeling activity following 
parathyroidectomy is accelerated and not 
just a return to baseline levels. Yet another 
possibility of osteoblast activation is the 
application of vitamin D or one of its avail-
able derivatives (calcitriol, paricalcitol, dox-
ercalciferol, and others). These compounds 
prevent the hungry bone syndrome after 
parathyroidectomy. In the study of Yajima 
et al.,10 alfacalcidol (1α-hydroxyvitamin 
D3) in doses of 0.5–2 µg per day was given 
for an undefined period of time after 
surgery. It is of note that any vitamin D 
compounds had been stopped for least 
2 months before surgery and were then 
restarted after surgery. In line with previous 
reports,11,12 alfacalcidol has recently been 
shown to directly stimulate remodeling as 
well as the de novo bone formation (mini-
modeling) in adult female rats.13 This sug-
gests that the activation of minimodeling 
after surgery might have been induced by 
withdrawal and then reapplication of alfa-
calcidol. Because the application of vitamin 
D compounds is part of the current stand-
ard of care after parathyroidectomy, it will 
be difficult to dissect its effects in humans. 
Well-designed animal experiments will be 
of value to investigate this matter. Another 
stimulus for the induction of minimode-
ling is the exertion of mechanical pressure 
on the bone tissue. Minimodeling can be 
induced by a minimum effective strain 
of more than 2,000 microstrain, whereas 
remodeling is already being induced by an 
applied pressure of less than 1,000 micro-
strain.5,7 In line with these data, outpatient 
hypopara t hyroid hemodialysis patients 
were found to exhibit more minimodeling 
activity than institutionalized, ill-mobi-
lizing patients.14 The patients reported by 
Yajima et al.10 regained physical activity 
immediately after surgery and presum-
ably reached presurgery activity levels 
within a reasonable time period. There-
fore physical activity probably was not the 
mechanism to induce minimodeling in this 
patient cohort.
Given the possibility that minimodeling 
is induced by vitamin D compounds, the 
question of whether vitamin D deriva-
tives should be given to patients with 
low-normal PTH or hypoparathyroidism 
comes up. The current 2003 Kidney Disease 
Outcomes Quality Initiative (K/DOQI) 
guidelines 13C.1 and 13C.1a recommend 
withholding calcium-based phosphate 
binders and active vitamin D to treat ady-
namic bone disease (determined by bone 
biopsy or low intact PTH levels <100 pg/
ml) in stage 5 CKD. This recommenda-
tion, based on expert opinion, reflects the 
fear of worsening adynamic bone disease 
with persistently low PTH levels. On the 
other hand, minimodeling seems to be a 
mechanism that can at least partially com-
figure 1 | Remodeling and minimodeling after parathyroidectomy for secondary 
hyperparathyroidism. Data adapted from Yajima et al.10
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pensate for the bone loss of adynamic bone 
disease.14 The clinically important question 
of whether adynamic bone disease is asso-
ciated with enhanced fracture risk has not 
been answered unequivocally.15,16 There-
fore, if bone is being formed de novo at 
trabecular sites important for bone stat-
ics, even small bone mass gains are prob-
ably beneficial. Chen et al. indicate that 
alfacalcidol induces minimodeling in rats 
at unique sites called boutons.13 These 
boutons connect adjacent trabeculae and 
increase trabecular thickness. Whether 
this leads to enhanced physical bone sta-
bility remains to be shown in large clinical 
or animal studies. However, currently it is 
tempting to speculate that the continuous 
application of vitamin D compounds might 
preserve bone mass in adynamic bone dis-
ease irrespective of their inhibitory effects 
on PTH synthesis. In this regard, different 
vitamin D derivatives—including 25OH-
vitamin D—could exhibit different effects 
and magnitudes of action. Consequently, 
to benefit from the potentially favorable 
impact of minimodeling, future K/DOQI 
guidelines might well recommend the con-
tinuation of some vitamin D sterols even in 
the presence of low PTH levels. The effect 
of calcimimetics on bone stability and frac-
ture rate was analyzed with a major portion 
of patients taking vitamin D sterols.17 As 
the treatment with calcimimetics lowers 
PTH levels, the bone-preserving effect 
might also—at least partially—depend on 
the additional action of some vitamin D 
derivative to induce and maintain mini-
modeling. It will be interesting to follow 
the course of future research in this field, 
which will certainly aim to fill this and 
other gaps in our knowledge.
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Let’s look at cysts  
from both sides now
Seth L. Alper1
In the years since identification of autosomal-dominant polycystic 
kidney disease (ADPKD) genes, the lag time between initial 
understanding and translation to therapy has decreased rapidly. 
Albaqumi and colleagues describe a promising approach to slow ADPKD 
cyst enlargement through inhibition of the basolateral KCa3.1 K+ 
channel, using a nontoxic small molecule with a close congener poised 
for rapid entry into the clinic. Cyst fluid accumulation can be blocked 
from both sides now.
Kidney International (2008) 74, 699–702. doi:10.1038/ki.2008.357
Autosomal-dominant polycystic kid-
ney disease (ADPKD) is the most com-
mon lethal monogenic disease, affecting 
between 0.025% and 0.25% of studied 
populations. The autosomal-dominant pat-
tern arises from a germline mutation and 
one or more hypothesized somatic second 
hits that may be allelic or oligogenic, lead-
ing to metaplastic change from epithelial 
tubule to cyst in 1%–3% of nephrons. 
Cystogenesis is accompanied by (and may 
arise from) ciliary dysfunction and loss of 
epithelial planar polarity in the context of 
accelerated proliferation and dedifferentia-
tion, either early in renal development or 
in the setting of (often subclinical) renal 
injury and repair. Cysts increase in size 
at a stable rate of 5%–6% per year, with 
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